ProtoKinetix, Incorporated (OTCPK: PKTX)
Health Care · Biotechnology · US
$0.00
-50.00% today · -97.1% 1Y
ProtoKinetix, Incorporated (OTCPK: PKTX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $82.33K and employs 5 people.
Over the last twelve months the share price has lost 97.1%, trading between 0.00 and 0.01.
Tweenvest scores ProtoKinetix, Incorporated across four factors: quality 18/100. Its strongest factor is quality.
PKTX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $82.33K
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.00
- Dividend yield
- —
- Beta (5Y)
- 0.73
- 52-week high
- $0.01
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 411.63M
- Employees
- 5
- Next earnings
- —
About ProtoKinetix, Incorporated
ProtoKinetix, Incorporated is a biotechnology firm engaged in research and development, specializing in the scientific and medical investigation of glycoproteins known as anti-freeze glycoproteins (AFGPs) and anti-aging glycoproteins (AAGPs). These AFGPs are particularly relevant for their commercial potential within the healthcare sector, with a key area of their development involving utilizing AAGPs for the treatment of dry-eye conditions. Their research efforts are bolstered by a collaborative agreement with the University of British Columbia. Originally incorporated in 1999 as RJV Network, Inc., the company adopted its current name, ProtoKinetix, Incorporated, in July 2003. Its operational headquarters are situated in Marietta, Ohio.
- ISIN
- US7437221002
- Founded
- 1999
- Listed since
- Apr 22, 2002
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $262.81 | -1.12% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $439.44 | -0.63% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.11 | -0.45% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $547.43 | -0.98% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $818.66 | -1.79% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $148.65 | -6.41% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.